Hikma must add an Advair study
Hikma has been told by the US Food and Drug Administration (FDA) to complete an additional clinical endpoint study to support its application for a generic version of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol), following a dispute-resolution process with the US agency. Hikma had received an FDA complete response letter (CRL) in May 2017 indicating that its abbreviated new drug application (ANDA) was not ready for approval (Generics bulletin, 19 May 2017, page 1). And following disagreement with the FDA over the firm’s clinical endpoint study, Hikma took the matter to the agency’s disputeresolution process (Generics bulletin, 17 November 2017, page 13). “Upholding its original determination”, the FDA has insisted on an additional clinical endpoint study.
You may also be interested in...
Hikma has received another setback on its US application for a generic version of Advair following a minor complete response letter from the FDA. The resulting delay will push back the expected final response date from the agency closer to that expected by rival Cipla, which filed an ANDA earlier this year.
Hikma has submitted a response to the US FDA addressing all outstanding deficiencies in its application for a generic version of GlaxoSmithKline’s Advair Diskus.
The challenges of developing a US generic of GlaxoSmithKline’s Advair Diskus fluticasone/salmeterol asthma blockbuster are thinning the field and improving the commercial prospects for those that succeed, Hikma believes.